Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...

The National Institute for Health and Care Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Superior rectal artery embolisation for haemorrhoids in ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

the recommendation is unreasonable in the light of the evidence submitted to NICE. NICE’s guide to the technology appraisal and highly specialised technologies appeal process sets out the arrangements ...

A list of downloadable documents created during development.

NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

For information the company have advised that they will no longer be making a submission, or making this gene therapy available in the UK. Therefore, in collaboration with the company, NICE has ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

Vamorolone (Agamree, Santhera) is indicated for 'the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older'. The anticipated list price of vamorolone is £4,585.87 per 100 ...